子宫切除/卵巢切除女性中激素治疗的 protective 作用
基于澳大利亚女性健康纵向研究13715名中年女性(1946-1951年出生)1998至2013年的随访数据,分析绝经激素治疗(MHT)与心血管疾病死亡及全因死亡的关系。现有使用者心血管死亡风险降低(HR 0.63;95%CI 0.43-0.92),全因死亡风险降低(HR 0.80;95%CI 0.70-0.91);新发起者全因死亡风险降低(HR 0.69;95%CI 0.55-0.87)。子宫切除/卵巢切除女性中保护作用更明显。
要点
- 现有MHT使用者心血管死亡风险较非发起者降低(HR 0.63;95%CI 0.43-0.92)。
- 新发起者全因死亡风险降低(HR 0.69;95%CI 0.55-0.87),现有使用者亦降低(HR 0.80;95%CI 0.70-0.91)。
- 子宫切除/卵巢切除女性中MHT与心血管死亡及全因死亡风险降低相关。
核心结论
- 绝经后不久使用MHT不太可能增加心血管死亡或全因死亡风险,可能对子宫切除/卵巢切除女性有保护作用。
- 考虑绝经后不久使用MHT的女性可放心,治疗不太可能增加心血管死亡或全因死亡风险。
研究设计与样本
- 澳大利亚女性健康纵向研究(ALSWH)中年人群队列(1946-1951年出生),共13715名参与者,1998年至2013年随访。
- 暴露为MHT使用和绝经状态(基于每3年自我报告),2002年中起有电子处方数据。
- 每次随访调查将参与者分类为:MHT现有使用者、MHT新发起者或非发起者。
主要发现
- 调整混杂因素后,现有使用者心血管死亡风险较非发起者降低(HR 0.63;95%CI 0.43-0.92)。
- 新发起者心血管死亡风险关联证据不足(HR 0.66;95%CI 0.35-1.24)。
- 全因死亡风险:新发起者降低(HR 0.69;95%CI 0.55-0.87),现有使用者降低(HR 0.80;95%CI 0.70-0.91)。
- 亚组分析:子宫切除/卵巢切除女性心血管死亡风险降低,新发起者HR 0.14(95%CI 0.02-0.98),现有使用者HR 0.55(95%CI 0.34-0.90);绝经期间或之后开始MHT的女性未发现关联证据。
- 子宫切除/卵巢切除女性全因死亡风险降低,新发起者HR 0.47(95%CI 0.31-0.70),现有使用者HR 0.69(95%CI 0.58-0.82)。
临床怎么用
- 作者认为,考虑绝经后不久使用MHT的女性可放心,治疗不太可能增加心血管死亡或全因死亡风险。
局限性
- 研究为观察性研究。
- 死亡人数少。
- MHT使用为自我报告。
- 绝经状态分类也基于自我报告信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does exposure to menopausal hormone therapy (MHT) in mid-aged women alter their risk of cardiovascular disease (CVD) mortality and all-cause mortality? SUMMARY ANSWER: MHT soon after menopause is unlikely to increase the risk of CVD mortality or all-cause mortality and may have a protective effect for women with hysterectomy/oophorectomy. WHAT IS KNOWN ALREADY: The balance of benefits and risks of MHT are currently unclear and may differ according to when treatment starts and whether women have an intact uterus. STUDY DESIGN SIZE, DURATION: A total of 13 715 participants from the mid-aged population-based cohort (born 1946-1951) of the Australian Longitudinal Study on Women's Health (ALSWH) were followed from 1998 to 2013. PARTICIPANTS/MATERIALS SETTING METHODS: The measures included cardiovascular and all-cause mortality, exposure to MHT and menopausal status (based on 3-yearly self-reports). Electronic prescriptions data on MHT were also available from mid-2002 onwards. At each follow-up survey wave, participants were classified as: an existing user of MHT, an initiator of MHT or a non-initiator of MHT. MAIN RESULTS AND THE ROLE OF CHANCE: After adjusting for confounding variables, existing users of MHT had a reduced risk (hazard ratio 0.63; 95% CI, 0.43-0.92) of CVD mortality compared with non-initiators. Insufficient evidence of an association was identified for initiators of MHT (0.66; 0.35-1.24). For all-cause mortality, risks were reduced for both initiators (0.69; 0.55-0.87) and existing users (0.80; 0.70-0.91). In a subgroup analysis, women with hysterectomy/oophorectomy had lower risks of CVD mortality for both initiators (0.14; 0.02-0.98) and existing users (0.55; 0.34-0.90), but no evidence of an association was found for women whose MHT commenced during or after menopause. Similarly for all-cause mortality, only the women with hysterectomy/oophorectomy had lower risks for both initiators (0.47; 0.31-0.70) and existing users (0.69; 0.58-0.82). LIMITATIONS, REASONS FOR CAUTION: Limitations include the observational nature of the study, the small number of deaths, MHT use being self-reported and the classification of menopausal status also being based on self-reported information. WIDER IMPLICATIONS OF THE FINDINGS: Women considering MHT soon after menopause can be reassured that the treatment is unlikely to increase their risk of CVD mortality or all-cause mortality. STUDY FUNDING/COMPETING INTEREST(S): The Australian Longitudinal Study on Women's Health is funded by the Australian Department of Health. G.D.M. is funded by the Australian Research Council Future Fellowship. L.C. was funded by a China scholarship council (CSC) graduate scholarship. All authors report no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Chen L, Mishra GD, Dobson AJ, et al. Protective effect of hormone therapy among women with hysterectomy/oophorectomy. Hum Reprod. 2017. PMID: 28184451. doi:10.1093/humrep/dex017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。